Emiltatug Biosimilar - Research Grade

Human

VTCN1

>1mg/ml

IgG1 - kappa

CHO Cells

Alsevalimab Biosimilar - Research Grade (ICH5339), Puxitatug Biosimilar - Research Grade (ICH5793)

https://www.imgt.org/mAb-DB/

ICH3002

Q7Z7D3

79679

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of emiltatug, a human IgG1-kappa antibody directed against VTCN1 (B7-H4). It reproduces the antigen-binding specificity of the originator without the payload or clinical formulation associated with the antibody-drug conjugate program from which emiltatug derives, making it suited to research applications rather than treatment. Because it binds the same B7-H4 target, it is a convenient tool for studying B7-H4 biology, benchmarking anti-B7-H4 reagents, and supporting method development. Typical uses include target-binding and specificity assays, epitope and affinity characterization, flow cytometry and immunoassay controls, and as a naked-antibody starting point for ADC or conjugation development and internalization studies. It is offered research-grade with low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support in-vitro and preclinical workflows. For research use only (RUO); this is not the clinical drug and is not intended for human or veterinary use. VTCN1, widely known as B7-H4 (also B7x, B7S1), is a type I transmembrane glycoprotein of the B7/CD28 immunoglobulin superfamily and functions as a co-inhibitory immune checkpoint. It negatively regulates T-cell responses, suppressing T-cell proliferation, cytokine production, and cytolytic activity, and can favor regulatory T-cell polarization, contributing to peripheral tolerance and immune evasion. Its counter-receptor on T cells has not been definitively identified. Expression is restricted in most healthy tissues but is frequently upregulated in epithelial cancers, including triple-negative and hormone-receptor-positive breast, ovarian, endometrial, and adenoid cystic carcinomas, where it correlates with an immunosuppressive tumor microenvironment. This tumor-associated overexpression and limited normal distribution make B7-H4 an attractive target for both checkpoint modulation and antibody-directed cytotoxic strategies.

B7 homolog 4, B7-H4, B7h.5, Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, V-set domain-containing T-cell activation inhibitor 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Emiltatug (anti-VTCN1) Biosimilar

Q: Is the Emiltatug biosimilar available in bulk or gram quantities?

A: Yes — the Emiltatug biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Emiltatug suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Emiltatug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Emiltatug that binds VTCN1.